Lancet Neurol .2015 Sep;14(9):914-25.

1 ICU Lancet Neurol . 2015 Sep;14(9):914-25. 1996/1/1 2015 /5/28 Posterior reversible encephalopathy syndrome(PRES) Reversible posterior leukoencephalopathy(RPLS) Review IntroducNon Posterior reversible encephalopathy syndrome(PRES) , IntroducNon Posterior reversible encephalopathy syndrome(PRES) , 20 IntroducNon Posterior reversible encephalopathy syndrome(PRES)

2 , Posterior reversible encephalopathy syndrome(PRES) , IntroducNon PRES Henoch- Sch nlein HUS Contents / Contents / Physiological condiNons of the blood-brain-barrier Tight juncNon Posterior reversible encephalopathy syndrome PRES Tight juncNon Posterior reversible encephalopathy syndrome.

3 The endothelial hypotheses Med hypotheses 2014;82:619-22 ICAM- VCAM- TNF- IL- VEGF Contents / The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% The neurological symptoms 50 80%

4 60 75% 50% 33% 10 15% 5 15% The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% PresentaNon of reversible posterior leukoencephalopathy syndrome in paNents on calcineurin inhibitors Clinical Neurology and Neurosurgery :112(2010)886-891 The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% PresentaNon of reversible posterior leukoencephalopathy syndrome in paNents on calcineurin inhibitors, Clin Neurol Neurosurg 2010 Vol.

5 112 886-891 The neurological symptoms 50 80% 60 75% 50% 33% 10 15% 5 15% Status epilepNcus as iniNal manifestaNon of posterior reversible encephalopathy syndrome Neurology Volume 69(9), August 2007, pp 894-897 Contents / CondiNons at risk for PRES PRES 15-20% PRES Blood Pressure FluctuaNons in Posterior Reversible Encephalopathy Syndrome J Stroke Cerebrovasc May;21(4):254-8.

6 CondiNons at risk for PRES Posterior Reversible Encephalopathy Syndrome , Part 1: Fundamental Imaging and Clinical Features AJNR Am J Neuroradiol 2008;29:1036-42 / CondiNons at risk for PRES PRES Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010 May;85(5):427-32. PRES Imaging pacern of intracranial hemorrhage in the sedng of posterior reversible encephalopathy syndrome. Neuroradiology 2010 Oct;52(10):855-63.

7 VEGF PRES Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012 Jan;105(1):69-75. Contents / Diagnosis PRES 1 1 PRES PRES Typical MRI findings in PRES A B C D E F G H I Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical Features AJNR Am J Neuroradiol 30.

8 1371 79 Aug 2009 PRES 10-25% 18-30% A ypical MRI regions in PRES Posterior Reversible Encephalopathy Syndrome: Incidence of Atypical Regions of Involvement and Imaging Findings American journal of roentgenology 2007;189:904-912 76 PRES retrospecNve 98% Contents / The differenNal diagnosis CNS Contents / Treatment RCT 25% 2013 ESH/ESC guidelines for the management of arterial hypertension.

9 The Task Force for the Management ofArterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology(ESC). Eur Heart J. 2013 Jul;34(28):2159-219. doi: Epub 2013 Jun 14. Contents / Prognosis 75-90% Posterior reversible encephalopathy syndrome induced by anN-VEGF agents. Target Oncol. 2011 Dec;6(4):253-8. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry 2010; 81: 773 77 10-20% Clinical spectrum and criNcal care management of Posterior Reversible Encephalopathy Syndrome (PRES).

10 Med Sci Monit 2005; 11: CR549 53 Prognosis 5-10% Is hypertension predicNve of clinical recurrence in posterior reversible encephalopathy syndrome? J Clin Neurosci 2013; 20: 248 52 Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012;7(9):e44534. Epub 2012 Sep 14. 3-6% 1-3 Message PRES 25 PRES